Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit
September 17, 2021 at 08:00 am EDT
Share
Vaccinex, Inc. announced that Elizabeth Evans, PhD, Chief Operating Officer, is scheduled to present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit. The company’s SIGNAL-AD trial, a Phase 1/2 trial of pepinemab in patients diagnosed mild Alzheimer’s Disease (AD), is actively enrolling individuals living with AD. In cancer, the company is currently enrolling patients with recurrent or metastatic head and neck cancer in the Phase 1/2 KEYNOTE B84 trial which is evaluating the effectiveness of a combination of pepinemab with Merck’s KEYTRUDA® checkpoint inhibitor.
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimerâs disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.